Image of Treatment of Chronic Low Back Pain With Etoricoxib, a New Cyclo-oxygenase-2 Selective Inhibitor: Improvement in Pain and
Disability—A Randomized, Placebo-Controlled, 3-Month Trial

LITERATURE

Treatment of Chronic Low Back Pain With Etoricoxib, a New Cyclo-oxygenase-2 Selective Inhibitor: Improvement in Pain and Disability—A Randomized, Placebo-Controlled, 3-Month Trial


We evaluated etoricoxib, a novel COX-2–specific inhibitor, in 319 patients with chronic low back pain (LBP) in this double-blind, placebo-controlled trial. Patients were randomized to a 60 mg dose (n  103) or 90 mg dose (n  107) of etoricoxib, or placebo (n  109), daily for 12 weeks. The primary endpoint was low back pain intensity scale (Visual Analog Scale of 0- to 100-mm) timeweighted average change from baseline over 4 weeks. Other endpoints included evaluation over 3 months of low back pain intensity scale, Roland-Morris Disability Questionnaire (RMDQ), low back pain bothersomeness scale, patient- and investigator-global assessments, Patient Health Survey (MOS SF-12), rescue acetaminophen use, and discontinuation due to lack of efficacy


Availability

Orinox-002Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
The Journal of Pain, Vol 4, No 6 (August), 2003: pp 307-315
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous